Antiviral Effects of a Niobium‐substituted Heteropolytungstate on Hepatitis B Virus‐transgenic Mice

Qingmei Li,Hong Zhang,Yanfei Qi,Juan Wang,Juan Li,Junqi Niu
DOI: https://doi.org/10.1002/ddr.21586
2019-01-01
Drug Development Research
Abstract:To study the efficacy of a polyoxometalate, Cs2K4Na[SiW9Nb3O40]center dot H2O, as an antiviral treatment in HBV transgenic mice. HBV transgenic mice were treated with Cs2K4Na[SiW9Nb3O40]center dot H2O by intragastric administration. Adefovir and distilled water were administered as controls. Serum HBV DNA, liver HBV RNA levels were measured by quantitative RT-PCR. Serum HBsAg levels were measured by ELISA. The hepatitis B virus surface antigen (HBsAg) in liver cells was detected by immunohistochemistry (IHC). Pathological changes in the liver tissues were also observed by light and electron microscopy. Cs2K4Na[SiW9Nb3O40]center dot H2O significantly decreased serum HBsAg and HBV DNA levels. Cs2K4Na[SiW9Nb3O40]center dot H2O resulted in a 98% decrease in serum HBV DNA at 28 days, from 4.3 log(10) copies/ml at baseline to 2.5 log(10) copies/ml after treatment, and the inhibition rate of HBV DNA was higher than ADV at the same dose. The HBV replication levels in each group slightly increased at 7 days after withdrawal, but rebounded slightly more in the Cs2K4Na[SiW9Nb3O40]center dot H2O treatment group compared to the H2O control group (p < .05). There were no differences in HBV RNA levels. No significant differences were observed in the pathology, but there were decreased HBsAg levels in the Cs2K4Na[SiW9Nb3O40]center dot H2O-treated group compared to the control group. The results demonstrated that Cs2K4Na[SiW9Nb3O40]center dot H2O displayed potent anti-HBV activity in HBV transgenic mice and supported for future clinic study.
What problem does this paper attempt to address?